SCHEMBL2495679

SCHEMBL2495679

CC(N)CN1CCCC1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.71
TSHR P16473 2/20 0.53
CYP2C19 P33261 2/20 0.42
LMNA P02545 3/20 0.42
CHRM2 P08172 3/20 0.42
CHRM5 P08912 3/20 0.42
CHRM1 P11229 3/20 0.42
CHRM3 P20309 3/20 0.42
CYP2D6 P10635 2/20 0.42
ALDH1A1 P00352 2/20 0.42
APEX1 P27695 2/20 0.42
PMP22 Q01453 2/20 0.42
MAPK1 P28482 2/20 0.42
ALOX12 P18054 1/20 0.42
NFKB1 P19838 1/20 0.42
PER2 O15055 1/20 0.42
CYP1A2 P05177 1/20 0.42
CHRM4 P08173 1/20 0.42
CYP2C9 P11712 1/20 0.42
KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8234472 0.94 PIK3CD (0.63) PIK3CDTSHRCYP2C19LMNACHRM2
SCHEMBL31021598 0.92 PIK3CD (0.61) PIK3CDTSHRCYP2C19LMNACHRM2
SCHEMBL8283771 0.85 PIK3CD (0.67) PIK3CDTSHRCYP2C19LMNACHRM2
SCHEMBL1303006 0.83 PIK3CD (1.00) PIK3CDTSHRCYP2C19LMNACHRM2
Bromide SCHEMBL27700849 0.82 PIK3CD (0.96) PIK3CDTSHRCYP2C19LMNACHRM2
SCHEMBL11672326 0.81 PIK3CD (0.67) PIK3CDTSHRCYP2C19LMNACHRM2
SCHEMBL2794323 0.80 PIK3CD (0.71) PIK3CDTSHRCYP2C19LMNACHRM2
SCHEMBL9679884 0.80 PIK3CD (0.71) PIK3CDTSHRCYP2C19LMNACHRM2
SCHEMBL27758594 0.80 PIK3CD (0.60) PIK3CDTSHRCYP2C19LMNACHRM2
SCHEMBL21294384 0.79 PIK3CD (0.59) PIK3CDTSHRCYP2C19LMNACHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118459351-A Synthesis method of multifunctional N- (aminopropyl) amine compound 榆林中科洁净能源创新研究院 2024-08-09 CN disclosed
US-11840497-B2 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases PTC THERAPEUTICS, INC. (US) 2023-12-12 US disclosed
US-20210179542-A1 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES BIOELECTRON TECHNOLOGY CORPORATION 2021-06-17 US disclosed
CN-112080467-A Tumor infiltrating lymphocytes for adoptive cell therapy H.李莫菲特癌症中心研究院 2020-12-15 CN disclosed
CN-106659913-A Tumor infiltrating lymphocytes for adoptive cell therapy H.李莫菲特癌症中心研究院 2017-05-10 CN disclosed
EP-2945950-B1 ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE SANOFI SA (FR) 2017-03-01 EP disclosed
US-9290502-B2 Pteridines useful as HCV inhibitors and methods for the preparation thereof JANSSEN SCIENCES IRELAND UC (IE) 2016-03-22 US disclosed
US-20160002406-A1 BETA-AMINO ESTER COMPOUNDS AND USES THEREOF LIVING PROOF, INC. (US) 2016-01-07 US disclosed
CN-101023066-B Substituted triazines as prion protein ligands and their use to detect or remove prions PROMETIC BIOSCIENCES LTD 2013-10-30 CN disclosed
EP-1786788-B1 SUBSTITUTED TRIAZINES AS PRION PROTEIN LIGANDS AND THEIR USE TO DETECT OR REMOVE PRIONS PROMETIC BIOSCIENCES LTD (GB) 2012-05-09 EP disclosed
US-8030484-B2 Binding affinity; PROMETIC BIOSCIENCES LIMITED (GB) 2011-10-04 US disclosed
US-20080269224-A1 Substituted Triazines as Prion Protein Ligands and Their Use to Detect or Remove Prions PROMETIC BIOSCIENCES LIMITED (GB) 2008-10-30 US disclosed
CN-101023066-A Substituted triazines as prion protein ligands and their use to detect or remove prions PROMETIC BIOSCIENCES LTD (GB) 2007-08-22 CN disclosed
EP-1786788-A1 SUBSTITUTED TRIAZINES AS PRION PROTEIN LIGANDS AND THEIR USE TO DETECT OR REMOVE PRIONS Prometic Biosciences Ltd (GB) 2007-05-23 EP disclosed
WO-2006010915-A1 SUBSTITUTED TRIAZINES AS PRION PROTEIN LIGANDS AND THEIR USE TO DETECT OR REMOVE PRIONS PROMETIC BIOSCIENCES LIMITED (GB) 2006-02-02 WO disclosed
CN-1438991-A Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER CIMITED (US) 2003-08-27 CN disclosed
EP-1296938-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE Pfizer Limited (GB) 2003-04-02 EP disclosed
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER, INC. 2002-05-02 US disclosed
WO-2002002513-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE PFIZER LIMITED (GB) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269224-A1 Substituted Triazines as Prion Protein Ligands and Their Use to Detect or Remove Prions PRNP, CDR2, CRBN PIK3CD 4881/4885TSHR 215/4885CYP2C19 3469/4885
US-11840497-B2 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases FH, NLN, ACAA2 PIK3CD 2313/4885TSHR 2679/4885CYP2C19 4284/4885
US-20210179542-A1 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES FH, NLN, ACAA2 PIK3CD 2313/4885TSHR 2679/4885CYP2C19 4284/4885
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase ENGASE, ENPEP, CPN1 PIK3CD 4812/4885TSHR 2123/4885CYP2C19 658/4885
US-20160002406-A1 BETA-AMINO ESTER COMPOUNDS AND USES THEREOF AADAT, BCAT2, EBP PIK3CD 1856/4885TSHR 4165/4885CYP2C19 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.